Evidence map›Paper›PMID 42035092›Full record

ReviewCell communication and signaling : CCS2026

Tumor cell intrinsic mechanisms of immune escape.

Ganapathy Sriram, Ahmed Aquib, Robert Glassman, Raymond B Birge

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ganapathy SriramDepartment of Biological, Chemical and Environmental Sciences, Wheaton College, 26 E Main St, Norton, MA, 02766, USA. Sriram_ganapathy@wheatoncollege.edu.
Ahmed AquibDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers New Jersey Medical School, 205 South Orange Ave, Newark, NJ, 07103, USA.
Robert GlassmanDepartment of Medicine, Division of Hematology & Oncology, Weill Cornell Medicine, 525 East 68th Street, New York, NY, 10065, USA.
Raymond B BirgeDepartment of Microbiology, Biochemistry and Molecular Genetics, Center for Cell Signaling, Rutgers New Jersey Medical School, 205 South Orange Ave, Newark, NJ, 07103, USA. birgera@njms.rutgers.edu.

Funding

NIH HHS R01 CA260137-01
6 · The paper itself

Abstract

Cancer arises in a multi-step process involving acquisition of mutations, activation of oncogenes and the loss of tumor suppressive mechanisms in normal cells. Such intrinsic genetic events lead to cellular transformation and gain of aggressive traits including enhanced proliferation and survival, as well as invasion and metastasis of tumor cells. Recent evidence suggests that tumor cell-intrinsic signaling pathways can also lead to suppression of the immune response against tumor cells resulting in failure of cancer cells to be recognized and eliminated by the host immune system. Insights into the tumor-intrinsic mechanisms of immune escape will not only expand our understanding of tumor development and progression but help develop new combinations of therapeutic strategies in immuno-oncology to better align them with targeted therapeutics. Historically, the literature on oncogenes and tumor suppressor mechanisms has focused on signaling pathways leading to tumor cell proliferation, survival, and metastasis. Here, in this special thematic collection published in Cell Communication and Signaling ( https://link.springer.com/collections/dbbfcgaece ), we featured commentaries, review articles, and primary research articles that highlight recent work focused on the molecular and mechanistic links between intrinsic oncogenic signaling and mechanisms of immune escape. We conclude with commentary and open questions and challenges that remain in this emerging field.

Indexed as

NeoplasmsTumor EscapeAnimalsHumansSignal TransductionCell Intrinsic Immune EvasionDrug ResistanceTargeted Therapeutics

Identifiers

PMID42035092
PMCPMC13162447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.